Advertisement
Research Article| Volume 160, ISSUE 1, P1-8, September 18, 1998

Download started.

Ok

Early (1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats

      Abstract

      We assessed the incidence of hemorrhagic transformation and infarct volume after early intravenous infusion of recombinant human tissue plasminogen activator (rht-PA) in a newly developed rat cerebral embolic model. Male Wistar rats (n=60) were subjected to middle cerebral artery (MCA) occlusion by a single fibrin rich clot. One hour after embolization, rats were assigned to the following groups: (1) rht-PA treated group (n=20); (2) vehicle treated group (n=20); and (3) saline treated group (n=20). Neurological deficits, lodgement of a clot at the origin of the MCA, infarction volume and microscopic hemorrhage were measured. Animals exhibited moderate to severe neurological deficits 1 h after MCA occlusion in all groups. Administration of rht-PA significantly (P<0.05) reduced the incidence of lodgement of a clot at the origin of the MCA (30%) compared with the saline treated group (100%) and the vehicle treated group (80%). A significant (P<0.05) reduction of percent hemispheric infarct volume was detected between the saline (33.2±3.71%) and the rht-PA groups (19.4±3.3%). However, no significant difference was found in the total area of microscopic hemorrhage of the rht-PA (0.05±0.02 mm2), the vehicle (0.02±0.01 mm2), and the saline (0.03±0.02 mm2) treated groups. No significant difference of percent hemispheric infarct volume (P=0.08) was observed between the vehicle and the rht-PA treated groups. This study demonstrates that treatment with rht-PA reduced infarct volume without increasing intracerebral hemorrhage in rats with large cerebral infarction when treatment was initiated at 1 h of the onset of embolization.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Anderson JL, Karagounis L, Allen A, Bradford MJ, Menlove RL, Pryor TA. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991;15(68):166–70.

        • del Zoppo G.J
        • Copeland B.R
        • Anderchek K
        • Hacke W
        • Koziol J.A
        Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction.
        Stroke. 1990; 21: 596-601
        • del Zoppo G.J
        • Poeck K
        • Pessin M.S
        • Wolpert S.M
        • Furlan A.J
        • Ferbert A
        • Alberts M
        • Zivin J
        • Wechsler L
        • Busse O
        • Greenlee R.J
        • Brass L
        • Mohr J.P
        • Feldmann E
        • Hacke W
        • Kase C.S
        • Biller J
        • Gress D
        • Otis S.M
        Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.
        Ann Neurol. 1992; 32: 78-86
        • Hacke W
        • Kaste M
        • Fieschi C
        • Toni D
        • Lesaffre E
        • von Kummer R
        • Boysen G
        • Bluhmki E
        • Hoxter G
        • Mahagne M.-H
        • Hennerici M
        Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study.
        J Am Med Assoc. 1995; 274: 1017-1025
        • Hacke W
        • Schwab S
        • Horn M
        • Spranger M
        • De Georgia M
        • von Kummer R
        `Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs.
        Arch Neurol. 1996; 53: 309-315
        • Hamann G.F
        • Okada Y
        • del Zoppo G.J
        Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion.
        J Cereb Blood Flow Metab. 1996; 16: 1373-1378
        • Hamilton M.G
        • Lee J.S
        • Cummings P.J
        • Zabramski J.M
        A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits.
        Stroke. 1994; 25: 651-656
        • Heiss W.D
        • Graf R
        • Lottgen J
        • Ohta K
        • Fujita T
        • Wagner R
        • Grond M
        • Weinhard K
        Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion.
        J Cereb Blood Flow Metab. 1997; 17: 388-400
        • Jiang N
        • Zhang R.L
        • Chen H
        • Chopp M
        Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient (2 h) but not after permanent MCA occlusion in the rat.
        Neurosci Res Comm. 1994; 15: 85-93
        • Jiang Q
        • Zhang R.L
        • Zhang Z.G
        • Ewing J.R
        • Jiang P
        • Chopp M
        Evaluation of cerebral artery embolic stroke and rt-PA intervention using diffusion, perfusion and T2 weighted NMR imaging in rat.
        J Cereb Blood Flow Metab. 1997; 17: S326
        • Jorgensen L
        • Torvik A
        Ischaemic cerebrovascular diseases in an autopsy series. 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts..
        J Neurol Sci. 1969; 9: 285-320
        • Larrue V
        • von Kummer R
        • del Zoppo G
        • Bluhmki E
        Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study.
        Stroke. 1997; 28: 957-960
        • Levy D.E
        • Brott T.G
        • Haley Jr., E.C
        • Marler J.R
        • Sheppard G.L
        • Barsan W
        • Broderick J.P
        Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
        Stroke. 1994; 25: 291-297
        • Lyden P.D
        • Zivin J.A
        Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence.
        Cerebrovasc Brain Metab Rev. 1993; 5: 1-16
        • Lyden P.D
        • Zivin J.A
        • Soll M
        • Sitzer M
        • Rothrock J.F
        • Alksne J
        Intracerebral hemorrhage after experimental embolic infarction.
        Arch Neuro. 1987; 44: 848-850
        • Morikawa E
        • Moskowitz M.A
        • Huang Z
        • Yoshida T
        • Irikura K
        • Dalkara T
        L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat.
        Stroke. 1994; 25: 429-435
      2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–7.

        • Overgaard K
        • Sereghy T
        • Boysen G
        • Pedersen H
        Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model.
        Scand J Clin Invest. 1993; 53: 383-393
        • Overgaard K
        • Sereghy T
        • Boysen G
        • Pedersen H
        • Hoyer S
        • Diemer N.H
        A rat model of reproducible cerebral infarction using thrombotic blood clot emboli.
        J Cereb Blood Flow Metab. 1992; 12: 484-490
        • Overgaard K
        • Sereghy T
        • Pedersen H
        • Boysen G
        Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model.
        J Cereb Blood Flow Metab. 1994; 14: 472-477
        • Papadopoulos S.M
        • Chandler W.F
        • Salamat M.S
        • Topol E.J
        • Sackellarees J.C
        Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
        J Neurosurg. 1987; 67: 394-398
        • Penar P.L
        • Greer C.A
        The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia.
        Yale J Biol Med. 1987; 60: 233-243
        • Phillips D.A
        • Fisher M
        • Smith T.W
        • Davis M.A
        The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model.
        Ann Neurol. 1988; 23: 391-394
        • Ringelstein E.B
        • Biniek R
        • Weiller C
        • Ammeling B
        • Nolte P.N
        • Thron A
        Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization.
        Neurology. 1992; 42: 289-298
        • Saku Y
        • Choki J
        • Waki R
        • Masuda J
        • Tamaki K
        • Fujishima M
        • Ogata J
        Hemorrhagic infarct induced by arterial hypertension in cat brain following middle cerebral artery occlusion.
        Stroke. 1990; 21: 589-595
        • Slivka A
        • Pulsinelli W
        Hemorrhagic complications of thrombolytic therapy in experimental stroke.
        Stroke. 1987; 18: 1148-1156
        • Swanson R.A
        • Morton M.T
        • Tsao-Wu G
        • Savalos R.A
        • Davidson C
        • Sharp F.R
        A semiautomated method for measuring brain infarct volume.
        J Cereb Blood Flow Metab. 1990; 10: 290-293
        • Thomas G.R
        • Thibodeaux H
        • Errett C.J
        • Badillo J.M
        • Keyt B.A
        • Refino C.J
        • Zivin J.A
        • Bennett W.F
        A long half-life and fibrin specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
        Stroke. 1994; 25: 2072-2078
        • Zea Longa Z
        • Weinstein P.R
        • Carlson S
        • Cummins R
        Reversible middle cerebral artery occlusion without craniectomy in rats.
        Stroke. 1989; 20: 84-91
        • Zhang R.L
        • Chopp M
        • Zhang Z.G
        • Jiang Q
        A rat model of focal embolic cerebral ischemia.
        Brain Res. 1997; 766: 83-92
        • Zivin J.A
        • Fisher M
        • DeGirolami U
        • Hemenway C.C
        • Stashak J.A
        Tissue plasminogen activator reduces neurological damage after cerebral embolism.
        Science. 1985; 230: 1289-1292
        • Zivin J.A
        • Lyden P.D
        • DeGirolami U
        • Kochhar A
        • Mazzarella V
        • Hemenway C.C
        • Johnston P
        Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke.
        Arch Neurol. 1988; 45: 387-391